Combination Therapies for the Treatment of Alzheimer's Disease and Related Disorders
The present invention relates to combination therapies for treating Alzheimer's disease or an amyloidosis-associated pathological condition comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound. In certain embodiments, the first compound or the second compound inhibits AB peptide polymerization; is an anti-inflammatory; improves cognitive function, mood, or social behavior; is associated with Tau or alpha-synuclein; or regulates amyloid peptide washout.
1 - 20 . (canceled)
21 . A method of treating a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
22 . A method of slowing the progression of a disease or condition in a subject in need thereof comprising co-administering a therapeutically effective amount of a first compound, and a therapeutically effective amount of a second compound, wherein the disease or condition is Alzheimer's disease, dementia, an amyloidosis-associated condition, or a head injury.
23 . The method of claim 21 , wherein the first compound and the second compound regulate amyloid peptide washout.
24 . The method of claim 22 , wherein the first compound and the second compound regulate amyloid peptide washout.
25 . The method of claim 23 , wherein the compounds that regulate amyloid peptide washout are Aβ peptide specific antibodies.
26 . The method of claim 25 , wherein the Aβ peptide specific antibodies are selected from the group consisting of bapineuzumab, solanezumab, gammaglobulin IV, and PF-4360365.
27 . The method of claim 23 , wherein the compounds that regulate amyloid peptide washout are anti-beta amyloid vaccines.
28 . The method of claim 27 , wherein the anti-beta amyloid vaccines are ACC-001 (Elan/Johnson & Johnson).
29 . The method of claim 23 , wherein the compounds that regulate amyloid peptide washout are siRNAs that target Aβ peptide.
30 . The method of claim 23 , wherein the compounds that regulate amyloid peptide washout are nerve growth factor (NGF) gene therapy.
31 . The method of claim 30 , wherein the nerve growth factor (NGF) gene therapy is CERE-110 (Ceregene Inc.).
32 . The method of claim 23 , wherein the compounds that regulate amyloid peptide washout are gamma-secretase inhibitors.
33 . The method of claim 32 , wherein the gamma-secretase inhibitors are either Semagacestat (LY450139) or NIC5-15 (Humanetics).
34 . The method of claim 24 , wherein the compounds that regulate amyloid peptide washout are Aβ peptide specific antibodies.
35 . The method of claim 34 , wherein the Aβ peptide specific antibodies are selected from the group consisting of bapineuzumab, solanezumab, gammaglobulin IV, and PF-4360365.
36 . The method of claim 24 , wherein the compounds that regulate amyloid peptide washout are anti-beta amyloid vaccines.
37 . The method of claim 36 , wherein the anti-beta amyloid vaccines are ACC-001 (Elan/Johnson & Johnson).
38 . The method of claim 24 , wherein the compounds that regulate amyloid peptide washout are siRNAs that target Aβ peptide.
39 . The method of claim 24 , wherein the compounds that regulate amyloid peptide washout are nerve growth factor (NGF) gene therapy.
40 . The method of claim 39 , wherein the nerve growth factor (NGF) gene therapy is CERE-110 (Ceregene Inc.).
41 . The method of claim 24 , wherein the compounds that regulate amyloid peptide washout are gamma-secretase inhibitors.
42 . The method of claim 41 , wherein the gamma-secretase inhibitors are either Semagacestat (LY450139) or NIC5-15 (Humanetics).